Preview

Современная ревматология

Расширенный поиск

Генно-инженерные биологические препараты в терапии системной красной волчанки

https://doi.org/10.14412/1996-7012-2013-11

Полный текст:

Аннотация

Системная красная волчанка (СКВ) является прототипом хронического аутоиммунного заболевания. Распространенность СКВ составляет от 20 до 70 случаев на 100 тыс. женщин и варьирует в зависимости от расовой и этнической принадлежности. Несмотря на значительные успехи традиционной терапии, многие проблемы, связанные с ведением этих больных, требуют незамедлительного решения: так у 50-80% больных СКВ выявляются признаки активности и/или частые обострения, около 30% вынуждены прекратить работу, наличие IV класса волчаночного нефрита увеличивает риск развития терминальной почечной недостаточности. За последние 20 лет достигнут огромный прогресс в изучении патогенеза СКВ: найдены биологические мишени для воздействия лекарственных средств и определены принципиально новые терапевтические задачи. Белимумаб – первый генно-инженерный биологический препарат, созданный специально для лечения СКВ, что по праву рассматривается как одно из наиболее крупных достижений ревматологии за последние 50 лет.

Об авторах

Елена Александровна Асеева
ФГБУ «Научно-исследовательский институт ревматологии им. акад. В.А. Насоновой» РАМН, Москва
Россия


Сергей Константинович Соловьев
ФГБУ «Научно-исследовательский институт ревматологии им. акад. В.А. Насоновой» РАМН, Москва


Евгений Львович Насонов
ФГБУ «Научно-исследовательский институт ревматологии им. акад. В.А. Насоновой» РАМН, Москва


Литература

1. <div><p>Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. DOI: 10.1056%2FNEJMoa021933.</p><p>James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol. 2006;18(5):462–7. DOI: 10.1097%2F01.bor.0000240355.37927.94.</p><p>Costenbader KH, Gay S, Alarcón-Riquelme ME et al. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2012;11(8):604-9. DOI: 10.1016/j.autrev.2011.10.022. Epub 2011 Oct 25.</p><p>Pons-Estel GJ, Alarcón GS, Scofield L et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010; 39(4):257-68. DOI: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10.</p><p>Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18. DOI: 10.1191%2F0961203306lu2305xx.</p><p>Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25. DOI: 10.1002/art.23177.</p><p>Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7. DOI: 10.1002%2Fart.21955.</p><p>Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum, 2009;61(9):1152–8. DOI: 10.1002/art.24741.</p><p>Yelin E, Tonner C, Trupin L et al. Longitudinal study of the impact of incident organ anifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(2):169–75. DOI: 10.1002/acr.20669.</p><p>Rose BD, Appel GB. End-stage renal disease due to lupus nephritis. UpToDate, 2012 (http://www.uptodate.com/contents/end-stage-renal-disease-due-to-lupus -nephritis).</p><p>Fessler BJ, Alarcón GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80. DOI: 10.1002%2Fart.21039.</p><p>Slawsky KA, Fernandes AW, Fusfeld L et al. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken). 2011;63(9):1224–32. DOI: 10.1002/acr.20502.</p><p>Petri M et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677–86. DOI: 10.1002/art.34473.</p><p>Jordan B, Lutalo PMK, D’Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med. 2013;11:120. DOI: 10.1186/1741-7015-11-120.</p><p>Furie RA, Petri MA, Wallace DJ et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum. 2009;(61):1143–51.</p><p>Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–8. DOI: 10.1002%2F1529-0131%28200008%2943%3A8%3C1801%3A%3AAID-ANR16%3E3.0.CO%3B2-O.</p><p>Sanz I, Lee FE. B-cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326–37. DOI: 10.1038/nrrheum.2010.68.</p><p>Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44(12):1542–5. DOI: 10.1093%2Frheumatology%2Fkei080. Epub 2005 Sep 27.</p><p>Lindholm C, Börjesson-Asp K, Zendjanchi K et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–33. Epub 2008 Apr 1.</p><p>Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9. DOI: 10.1002%2Fart.20430 .</p><p>Turner-Stokes T, Lu TY, Ehrenstein MR et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011;50(8):1401–8. DOI: 10.1093/rheumatology/ker018. Epub 2011 Mar 12.</p><p>Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–66. DOI: 10.1002/art.27541.</p><p>Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60(Suppl 1):S429.</p><p>Lightstone L. The landscape after LUNAR: rituximab’s crater-filled path. Arthritis Rheum. 2012;64(4):962–5. DOI: 10.1002/art.34362. Epub 2012 Jan 9.</p><p>Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. DOI: 10.1002/art.27233.</p><p>Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717–23. DOI: 10.1093/ndt/gfp336. Epub 2009 Jul 17.</p><p>Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol. 2011;71(2):175–82. DOI: 10.1111/j.1365-2125.2010.03767.x.</p><p>Jacobi AM, Goldenberg DM, Hiepe F et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67(4):450–7. DOI: /10.1136%2Fard.2007.075762. Epub 2007 Aug 2.</p><p>FDA approves Benlysta to treat lupus. [Last accessed on 2011 Mar 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm</p><p>European Medicines Agency. Benlysta: belimumab. 9cited August 8, 2011). Available from: www.ema.ruropa.eu/ema/index/jsp?curl=pages/medicines/human/medicines.002015/human_med_001466.jsp&amp;mid=WC0bac058001d124</p><p>Lied GA, Berstad A. Functional and clinical aspects of the B cell-activation factor (BAFF): a narrative review. Scand J Immunol. 2011;73(1):1–7. DOI: 10.1111/j.1365-3083.2010.02470.x.</p><p>Moore PA, Belvedere O, Orr A. et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–3. DOI: 10.1126%2Fscience.285.5425.260.</p><p>Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–56. DOI: 10.1084%2Fjem.189.11.1747.</p><p>Treml JF, Hao Y, Stadanlick JE et al. The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1–16. DOI: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.</p><p>Gross JA, Johnston J, Murdi S et al. TACI and BCMA are receptors for TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995–9.</p><p>Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003;48(12):3475–86. DOI: 10.1002%2Fart.11354.</p><p>Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):2453–9.DOI: 10.1002/art.23678.</p><p>Sanz I. Targeting B-cell in SLE: good news at last. Nat Rev Rheum. 2011; 7(5):255-6. DOI: 10.1038/nrrheum.2011.48.</p><p>Halpern WG, Lappin P, Zanardi T et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects.Toxicol Sci. 2006;91(2):586–99. DOI: 10.1093%2Ftoxsci%2Fkfj148. Epub 2006 Mar 3.</p><p>Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65. DOI: /10.1002%2Fart.11299.</p><p>Label approved on 03/10/2011 (PDF) for BENLYSTA, BLA no.125370 [Last accessed 2011 Mar 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/12537</p><p>Navarra SV, Guzman RM, Gallacher AE et al. BLISS-52 Study Group.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.</p><p>Furie R, Petri M, Zamani E et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI: 10.1002/art.30613.</p><p>Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51. DOI: 10.1002/art.24698.</p><p>Furie R, Petri M, Zamani E et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI: 10.1002/art.30613.</p><p>Manzi S, Sanchez-Guerrero J, Merrill JT et al. Effects of belimumab,a B lymphocyte stimulator-specigic inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71(11):1833-8. DOI: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.</p><p>Van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012; 71(8):1343-9. DOI: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.</p><p>Jacobi AM, Odendahl M, Reiter K et al. Correlation between circulating CD29high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(5):1332–42. DOI: 10.1002%2Fart.10949</p><p>Petri M, Singh S, Tesfasyone H et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol. 2009;36(11):2476–80. DOI: 10.3899/jrheum.090019. Epub 2009 Oct 15.</p><p>Tseng CE, Buyon JP, Kim M et al. The effect of moderate dose corticosteroids in preventing of severe flares in patients with serologically active, but clinically stable systemic lupus erythematosus: finding of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(11):3623–32. DOI: 10.1002%2Fart.22198.</p><p>Merril JT, Ginzler EM, Wallace DJ et al. Long-term safety profile of belimumab plus standart therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(10):3364-73. DOI: 10.1002/art.34564.</p><p>Molta С et al. Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematous (SLE) in Clinical Practice Settings: Results from OBSErve Study in the United States (U.S.). Lupus. 22, Abstr Suppl; 036, 2013.</p><p>Ramos-Casals M et al. Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI. Rev Clin Esp. 2012; 213(1):66–7. DOI: 10.1016/j.rce.2012.10.004.</p></div><br />


Для цитирования:


Асеева Е.А., Соловьев С.К., Насонов Е.Л. Генно-инженерные биологические препараты в терапии системной красной волчанки. Современная ревматология. 2013;7(3):33-40. https://doi.org/10.14412/1996-7012-2013-11

For citation:


Aseeva E.A., Solovyev S.K., Nasonov E.L. Genetically engineered biological agents in therapy for systemic lupus erythematosus. Modern Rheumatology Journal. 2013;7(3):33-40. (In Russ.) https://doi.org/10.14412/1996-7012-2013-11

Просмотров: 2558


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)